Among patients with iRBD, altered visuospatial cue-elicited N2 and P3 ERPs predicted phenoconversion to α-synucleinopathies.

Discover the alarming rates of dementia diagnosis unawareness, ethnic disparities in diagnosis, and the implications for caregivers in a Texas cohort study.

Four out of five older adults who likely have dementia may be unaware of their condition, according to findings from a cohort ...

Post-stroke cognitive impairment (PSCI) and dementia affect short- and long-term outcome after stroke and can persist even after recover from a physical handicap. The process underlying PSCI is not ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital. Dr. Olivier Blanchard and his team want ...

Some of L.A.’s biggest arts institutions including the J. Paul Getty Trust, LACMA, MOCA and the Hammer Museum are among those backing an emergency reserve for artists and arts workers that stand ...

A man who was left unable to walk or talk by a neurological disorder has called for greater understanding of his condition after he was told to "get moving" by a GP. Liam Virgo, 22, was 13 when he ...

Secondary outcomes will include Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Barthel Index (BI ... primary progressive semantic aphasia, and other active ...

RBC Capital analyst Shagun Singh said the deal fit strategically into J&J's neurological drugs division, an important area for the company. Sales of J&J's neurological drugs But at least one ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

as well as SAGE-324 in essential tremor and other neurological disorders. The blockbuster deal featured an upfront payment of $875 million from Biogen and a $650 million equity investment in Sage.